欧洲药物监管者建议批准 AstraZeneca的膀胱癌治疗,Imfinzi。 European drug regulator recommends approval for AstraZeneca's bladder cancer treatment, Imfinzi.

欧洲医药署建议批准AstraZeneca的Imfinzi药物, 结合化疗治疗肌肉侵入性膀胱癌。 The European Medicines Agency has recommended approval for AstraZeneca's Imfinzi drug to treat muscle-invasive bladder cancer in combination with chemotherapy. 根据临床试验结果,治疗显示复发率减少了32%,死亡风险比单是化疗就减少了25%。 Based on clinical trial results, the treatment showed a 32% reduction in recurrence and a 25% reduction in death risk compared to chemotherapy alone. 如果获得批准,这将是欧盟首次对这种疾病进行这种类型的免疫疗法。 If approved, it would be the first immunotherapy of its kind for this condition in the EU.